Real-time Smoking Cessation Instant Messaging Support Using a Large Language Model (LLM)-Based Chatbot Via "Quit to Win" 2025 (QTW2025)
Launched by THE UNIVERSITY OF HONG KONG · Mar 31, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Quit to Win" 2025, is exploring whether a chatbot—an online program that can chat with you—can help people quit smoking. The researchers want to find out if using this chatbot for support can help smokers stop smoking more effectively than just getting standard advice from a healthcare provider. They will compare the success of participants who use the chatbot with those who receive usual care to see which method is more effective in helping people quit smoking.
To participate in this trial, you need to be a resident of Hong Kong, at least 18 years old, and currently smoke daily. You'll also need to be able to communicate in Chinese and use messaging apps like WhatsApp or WeChat. If you join the study, you'll receive personalized advice, a referral for further support, and access to the chatbot that provides counseling. This trial is not yet recruiting participants, but it aims to understand how helpful this new technology can be for smokers looking to quit.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hong Kong residents aged 18 or above
- • Smoke at least 1 tobacco stick (includes HTP) per day or use e-cigarette daily in the past 3-month
- • Able to communicate in Chinese
- • Exhaled carbon monoxide level ≥4 part per million or a positive salivary cotinine test
- • Intention to quit/reducing smoking
- • Have instant messaging tool (WhatsApp) installed
- • Able to use the instant messaging tool (e.g., WhatsApp) for communication
- Exclusion Criteria:
- • Smokers who have communication barriers (either physical or cognitive).
- • Smokers who are currently participating in other smoking cessation programs or services.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Man Ping Wang, PhD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported